Table 2 Clinical parameters compared post-treatment among the three groups
Patient | Duration from onset to treatment(days) | Duration from first visit to treatment(days) | Recurrence | Post-treatment ocular complications | Initital treatment | Final logMAR BCVA R | Final logMAR BCVA L | |
|---|---|---|---|---|---|---|---|---|
HLA-DRB1*04 +/+ | 9 | 37 | 11 | none | none | paluse | −0.176091259 | − 0.176091259 |
11 | 23 | 2 | none | none | paluse | −0.176091259 | 0 | |
13 | 14 | 1 | PSL increased | none | STTA(40 mg),paluse | −0.079181246 | −0.176091259 | |
16 | 11 | 9 | none | none | paluse | −0.176091259 | − 0.176091259 | |
20 | 12 | 1 | none | none | paluse | −0.176091259 | −0.176091259 | |
23 | 25 | 2 | none | Left cataract | paluse | −0.176091259 | −0.176091259 | |
25 | 9 | 4 | none | none | paluse | −0.079181246 | − 0.079181246 | |
27 | 23 | 8 | none | none | paluse | −0.079181246 | − 0.079181246 | |
HLA-DRB1*04 +/− | 2 | 7 | 2 | none | none | paluse | 0 | −0.079181246 |
4 | 14 | 6 | none | none | STTA(40 mg),paluse | −0.176091259 | −0.176091259 | |
5 | 40 | 2 | PSL increased | Left cataract | paluse | −0.079181246 | −0.079181246 | |
8 | 19 | 5 | none | none | paluse | −0.176091259 | −0.176091259 | |
10 | 12 | 7 | none | none | paluse | 0.301029996 | ||
12 | 21 | 0 | PSL increased | none | paluse | 0 | −0.079181246 | |
14 | 39 | 6 | PSL increased | none | paluse | −0.079181246 | −0.079181246 | |
17 | 6 | 1 | PSL resumed | none | PSL40mg,paluse | 0 | −0.079181246 | |
18 | 11 | 4 | none | none | paluse | −0.176091259 | −0.079181246 | |
19 | 6 | 1 | none | none | paluse | −0.176091259 | 0 | |
21 | 8 | 1 | none | none | paluse | −0.176091259 | −0.176091259 | |
22 | 23 | 1 | none | none | paluse | −0.176091259 | −0.176091259 | |
26 | 3 | 5 | none | none | paluse | −0.176091259 | −0.176091259 | |
28 | 14 | 12 | none | none | paluse | −0.176091259 | −0.176091259 | |
29 | 18 | 6 | none | none | paluse | −0.176091259 | −0.176091259 | |
HLA-DRB1*04 −/− | 1 | 16 | 2 | none | none | paluse | −0.079181246 | −0.079181246 |
3 | 13 | 7 | none | Both cataract | palse | 0 | 0.15490196 | |
6 | 17 | 6 | none | none | STTA(40 mg),paluse | 1 | 0.301029996 | |
7 | 20 | 1 | none | none | paluse | −0.176091259 | 0 | |
15 | 4 | 4 | none | none | PSL30mg | −0.176091259 | −0.176091259 | |
24 | 42 | 4 | none | none | paluse | −0.176091259 | −0.176091259 | |
P-value | 0.586* | 0.87* | 0.645* | 0.301* |